retatrutide safety trial Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA What Not to Take With

BMC Genom 16(1):1076 Wright VJ, Herberg JA, Kaforou M, Shimizu C, Eleftherohorinou H, Shailes H et al (2018) Diagnosis of Kawasaki disease using a minimal whole-blood gene expression signature

Trials of anti-inflammatory agents increased from three in 2023 to seven in 2024, due to new trials targeting NLRP3, a key component of the inflammasome

Bm-TFF2, a toad trefoil factor, promotes cell migration, survival and wound healing

Antidepressive medication aids in the restoration of neurometabolite homeostasis to normal level

Copper tripeptide-3 increases dermal cell proliferation and viability while increasing the deposition of collagen to renew the extracellular matrix